CANBRIDGE PHARM.DL-00001 (F:MF1) — Stock Price
CANBRIDGE PHARM.DL-00001 (F:MF1) is currently trading at €0.18 EUR, down 5.85% today. Over the past 52 weeks, shares have ranged between €0.15 and €0.29. This page tracks CANBRIDGE PHARM.DL-00001's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see CANBRIDGE PHARM.DL-00001 (MF1) total market value.
CANBRIDGE PHARM.DL-00001 (MF1) Stock Price Chart — Daily History & Trading Volume
The chart below tracks CANBRIDGE PHARM.DL-00001's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
CANBRIDGE PHARM.DL-00001 Income Statement — Revenue, Profit & Earnings by Year
CANBRIDGE PHARM.DL-00001's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €49.98 Million | €85.10 Million | €102.87 Million | €78.97 Million | €31.16 Million |
| Cost of Revenue | €12.66 Million | €30.80 Million | €38.71 Million | €30.08 Million | €12.38 Million |
| Gross Profit | €37.33 Million | €54.30 Million | €64.16 Million | €48.89 Million | €18.78 Million |
| Research & Development | €45.05 Million | €251.76 Million | €257.21 Million | €311.17 Million | €427.66 Million |
| SG&A | €84.20 Million | €143.06 Million | €173.50 Million | €195.69 Million | €246.26 Million |
| Total Operating Expenses | €141.55 Million | €424.91 Million | €467.99 Million | €528.49 Million | €685.90 Million |
| Operating Income | €-91.56 Million | €-339.81 Million | €-365.11 Million | €-449.51 Million | €-654.74 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €2.23 Million | €8.58 Million | €8.95 Million | €6.86 Million | €3.08 Million |
| Income Before Tax | €14.82 Million | €-442.62 Million | €-378.84 Million | €-483.48 Million | €-1.08 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €14.82 Million | €-442.62 Million | €-378.84 Million | €-483.48 Million | €-1.08 Billion |
CANBRIDGE PHARM.DL-00001 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes CANBRIDGE PHARM.DL-00001's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €165.39 Million | €116.81 Million | €395.36 Million | €702.04 Million | €892.52 Million |
| Total Current Assets | €110.17 Million | €45.35 Million | €209.86 Million | €505.16 Million | €811.71 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | €15.12 Million | €16.72 Million | €31.23 Million | €19.05 Million | €9.14 Million |
| Inventory | €20.57 Million | €7.90 Million | €8.78 Million | €9.82 Million | €13.45 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €507.15 Million | €591.30 Million | €435.15 Million | €393.49 Million | €199.13 Million |
| Total Current Liabilities | €455.34 Million | €482.61 Million | €327.94 Million | €278.11 Million | €185.78 Million |
| Long-term Debt | €8.00 Million | €15.04 Million | €6.62 Million | €10.78 Million | €0.00 |
| Net Debt | — | €20.34 Million | — | — | — |
| Total Stockholder Equity | €-341.75 Million | €-474.49 Million | €-39.79 Million | €308.56 Million | €693.39 Million |
| Retained Earnings | €-4.19 Billion | €-4.21 Billion | €-3.79 Billion | €-3.41 Billion | €-2.93 Billion |
CANBRIDGE PHARM.DL-00001 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how CANBRIDGE PHARM.DL-00001 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-38.21 Million | €-122.39 Million | €-278.23 Million | €-280.98 Million | €-587.07 Million |
| Capital Expenditures | €6.00K | €105.00K | €40.86 Million | €34.79 Million | €5.33 Million |
| Free Cash Flow | €-38.22 Million | €-122.50 Million | €-319.09 Million | €-315.76 Million | €-592.40 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €5.07 Million | €7.69 Million | €19.92 Million | €26.82 Million | €30.51 Million |
| Depreciation | €12.15 Million | €27.25 Million | €28.46 Million | €21.98 Million | €15.71 Million |
| Change in Cash | €55.48 Million | €-127.03 Million | €-333.10 Million | €-336.47 Million | €393.33 Million |
CANBRIDGE PHARM.DL-00001 Earnings History — EPS Actual vs. Analyst Estimates
Track CANBRIDGE PHARM.DL-00001's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for CANBRIDGE PHARM.DL-00001.